{"doi":"10.1192\/bjp.184.4.346","coreId":"206467","oai":"oai:eprints.lse.ac.uk:15081","identifiers":["oai:eprints.lse.ac.uk:15081","10.1192\/bjp.184.4.346"],"title":"Relapse in schizophrenia: costs, clinical outcomes and quality of life","authors":["Almond, Stephen","Knapp, Martin","Francois, Clement","Toumi, Mondher","Brugha, Traolach"],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2004-04","abstract":"Background: Relapse is one of the most costly aspects of schizophrenia.\\ud\n\\ud\nAims: To compare costs, clinical outcomes and quality of life for patients who experienced relapse in schizophrenia with a control group who did not relapse.\\ud\n\\ud\nMethod: Patients were randomly selected from current psychiatric case-loads drawn from urban and suburban areas of Leicester. Differences in costs and outcomes by relapse status in the previous 6 months were examined using parametric and non-parametric tests, and multivariate analysis was used to examine factors associated with relapse and costs.\\ud\n\\ud\nResults: Costs for the patients who relapsed were over four times higher than those for the non-relapse group. There were few statistically significant differences in clinical and quality of life measures by relapse status. Multivariate analyses suggested some significant correlates of relapse and costs.\\ud\n\\ud\nConclusions: The higher costs associated with relapse will be of interest to policy-makers who face difficultchoices concerning new but more expensive treatments for patients with schizophrenia","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":"Royal College of Psychiatrists","rawRecordXml":"<record><header><identifier>\n    \n    \n      oai:eprints.lse.ac.uk:15081<\/identifier><datestamp>\n      2012-05-30T08:36:12Z<\/datestamp><setSpec>\n      74797065733D4445505453:4C53452D5341<\/setSpec><setSpec>\n      74797065733D43454E54524553:4C53455F52435F3536<\/setSpec><setSpec>\n      74797065733D43454E54524553:4C53455F52435F3839<\/setSpec><setSpec>\n      74797065733D43454E54524553:4C53455F52435F4E53534352<\/setSpec><\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:relation>\n    \n      \n        http:\/\/eprints.lse.ac.uk\/15081\/<\/dc:relation><dc:title>\n        Relapse in schizophrenia: costs, clinical outcomes and quality of life<\/dc:title><dc:creator>\n        Almond, Stephen<\/dc:creator><dc:creator>\n        Knapp, Martin<\/dc:creator><dc:creator>\n        Francois, Clement<\/dc:creator><dc:creator>\n        Toumi, Mondher<\/dc:creator><dc:creator>\n        Brugha, Traolach<\/dc:creator><dc:subject>\n        R Medicine (General)<\/dc:subject><dc:subject>\n        HV Social pathology. Social and public welfare. Criminology<\/dc:subject><dc:description>\n        Background: Relapse is one of the most costly aspects of schizophrenia.\\ud\n\\ud\nAims: To compare costs, clinical outcomes and quality of life for patients who experienced relapse in schizophrenia with a control group who did not relapse.\\ud\n\\ud\nMethod: Patients were randomly selected from current psychiatric case-loads drawn from urban and suburban areas of Leicester. Differences in costs and outcomes by relapse status in the previous 6 months were examined using parametric and non-parametric tests, and multivariate analysis was used to examine factors associated with relapse and costs.\\ud\n\\ud\nResults: Costs for the patients who relapsed were over four times higher than those for the non-relapse group. There were few statistically significant differences in clinical and quality of life measures by relapse status. Multivariate analyses suggested some significant correlates of relapse and costs.\\ud\n\\ud\nConclusions: The higher costs associated with relapse will be of interest to policy-makers who face difficultchoices concerning new but more expensive treatments for patients with schizophrenia.<\/dc:description><dc:publisher>\n        Royal College of Psychiatrists<\/dc:publisher><dc:date>\n        2004-04<\/dc:date><dc:type>\n        Article<\/dc:type><dc:type>\n        PeerReviewed<\/dc:type><dc:identifier>\n          Almond, Stephen and Knapp, Martin and Francois, Clement and Toumi, Mondher and Brugha, Traolach  (2004) Relapse in schizophrenia: costs, clinical outcomes and quality of life.  British Journal of Psychiatry, 184 (4).  pp. 346-351.  ISSN 0007-1250     <\/dc:identifier><dc:relation>\n        http:\/\/bjp.rcpsych.org<\/dc:relation><dc:relation>\n        10.1192\/bjp.184.4.346<\/dc:relation><\/oai_dc:dc><\/metadata><\/record>","journals":null,"language":null,"relations":["http:\/\/eprints.lse.ac.uk\/15081\/","http:\/\/bjp.rcpsych.org","10.1192\/bjp.184.4.346"],"year":2004,"topics":["R Medicine (General)","HV Social pathology. Social and public welfare. Criminology"],"subject":["Article","PeerReviewed"],"fullText":null}